<DOC>
	<DOCNO>NCT01363817</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose BMS-906024 , either alone combination Dexamethasone subject T-cell acute lymphoblastic leukemia T-cell lymphoblastic lymphoma longer respond relapsed standard therapy</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability Weekly Intravenous ( IV ) Doses BMS-906024 Subjects With Acute T-cell Lymphoblastic Leukemia T-cell Lymphoblastic Lymphoma</brief_title>
	<detailed_description>Minimum Age : 10 year older select site</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects Tcell acute lymphoblastic leukemia Tcell lymphoblastic lymphoma refractory relapse standard therapy Life expectancy least 2 month Performance status ( PS ) 01 ( measure ability carry activity daily live ) ; subject PS 2 eligible due disease relate symptom Prior anticancer treatment permit ( specific criterion ) Adequate organ function Infection Elevated triglycerides Gastrointestinal disease increase risk diarrhea ( e.g . inflammatory bowel disease ) Unable tolerate bone marrow biopsy Taking medication know increase risk Torsades De Pointes ( abnormal heart rhythm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>